Shiga Microalbuminuria Reduction Trial-2

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 237 participants.

Also called NCT01461499

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 237 participants (enrolled count) (from the registry)
Sponsor
Shiga University (from the registry)
Registry
  • NCT NCT01461499
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01461499. Randomized; no masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2018-02-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Shiga Microalbuminuria Reduction Trial-2
Condition
Type 2 Diabetes Mellitus
Condition
Hypertension
Intervention (Drug)
Aliskiren
Intervention (Drug)
any angiotensin receptor blockers
Lead sponsor
Shiga University (class: other)

Record details

Record id
cardio:ct-nct01461499
Content hash
aad6caa7c4a6ea70477db369a1da4a27e3731a8b38ebef92597279361ace76c0